Neuropsychiatric and Neurodevelopmental Disorders

Neuropsychiatric and Neurodevelopmental Disorders result from both genetic and environmental factors and have great impacts in terms of global burden of disease ranking fifth globally in causes of disability. These disorders are associated with considerable morbidity and increased rates of mortality due to suicide and ill health and cost (due to health care, disability, and lost income). The human impact of a severe mental illness on the lives of the people afflicted and their families and communities is often profound. In addition, empirical studies have demonstrated the effectiveness of social, psychological, and/or pharmacological therapies for all of these disorders. These are treatable conditions and treatment often leads to marked improvements in symptoms and quality of life. However, particularly for severe psychiatric disorders, current therapies may only mitigate symptoms.

GNC researchers, in association with NICOG and ICAN, have been involved in examining the neurobiological mechanisms and novel treatment targets for a host of neuropsychiatric and neurodevelopmental conditions, with an aim to improving quality of life for individuals with these disorders.

 Relevant Research groups